Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat will be the outcome of Pfizer's danuglipron dosage optimization studies in the second half of 2024?
Successful with significant efficacy • 25%
Successful with moderate efficacy • 25%
Unsuccessful due to adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Pfizer's official announcements, press releases, or clinical trial registries
Pfizer Advances Development of Once-Daily Weight-Loss Pill Danuglipron with 2024 Trials
Jul 11, 2024, 12:04 PM
Pfizer is advancing the development of a once-daily formulation of its experimental weight-loss pill, danuglipron, which targets the multibillion-dollar market for obesity medications. The company announced on Thursday it will conduct dose optimization studies in the second half of 2024 after obtaining promising pharmacokinetic results for the modified release formulation. This decision follows the scrapping of a twice-daily version of the drug late last year. Danuglipron is a GLP-1 receptor agonist, and Pfizer aims to determine the optimal dosage in upcoming clinical trials later this year after getting promising data from an early-stage trial.
View original story
Highly positive • 25%
Moderately positive • 25%
Neutral • 25%
Negative • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Approved in the US • 25%
Approved in the EU • 25%
Approved in both US and EU • 25%
Not approved • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
Study inconclusive • 25%
Reduction by <25% • 25%
Reduction by 25-50% • 25%
Reduction by 50-75% • 25%
Reduction by >75% • 25%
Positive results • 33%
Negative results • 33%
Inconclusive results • 34%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
Less than 10% • 25%
More than 30% • 25%
20% to 30% • 25%
10% to 20% • 25%